A Case of Sweet Syndrome

Save

This overview appeared in JAMA Dermatology.

ZEUS Trial: IL-6 Inhibition Fails to Cut Cardiovascular Events

Save

The phase 3 ZEUS trial (published in JAMA Dec. 2025)  tested the IL-6 ligand inhibitor ziltivekimab in over 6,000 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated hsCRP—a population enriched for an inflammatory driver of risk.

2026 BSR Pain Guideline: What Rheumatologists Need to Know

Save

The British Society for Rheumatology has issued its first guideline dedicated solely to pain in inflammatory arthritis (IA)—covering RA, PsA, axial SpA and JIA.

Updated Guidance for Artificial Intelligence Use in Medical Publications

Save

JAMA has updated its guidance for the acceptable use of artificial intelligence (AI) in authoring a medical publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. This update provides specific information about what is permitted and not permitted, and what needs to be disclosed.

Evaluating Inflammatory Joint Pain in Older Adults

Save

Lee, Levinson, and Makris have published an approach to evaluating inflammatory joint pain in older adults in JAMA Internal Medicine. While intended to be a practical guide for primary care clinicians, the tenets and clues ring true for all.

Wealth and Where you Live Influences Outcomes

Save

Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and low-income countries.

What's New in Lyme Disease

Save

JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention.

POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA

Save

POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in psoriatic arthritis (PsA) patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, and structural damage inhibition in PsA.

Mentshlichkeit* (8.7.2026)

Save

Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com.

Air Pollution Increases RA Activity and Flares

Save

In this study from Korea, levels of small particulate matter correlated with increased RA disease activity and risk for disease flares.

Rethinking Treatment of EGPA

Save

Eosinophilic granulomatosis with polyangiitis (EGPA) has long been managed by extrapolating results from microscopic polyangiitis and granulomatosis with polyangiitis clinical trials. But new insights into EGPA's has lead to advances in therapy and new treatment paradigms.

Top 20 Best Rheumatology Hospitals

Save

U.S. News & World Report has published its Best Hospitals for 2026-2027, listing the best among many specialties, including rheumatology.  Each year U.S. News Best Hospitals ranked hospitals in the U.S.

Keep HCQ Blood Levels Up to Avoid Cardiovascular Disease in Lupus

Save

People taking hydroxychloroquine (HCQ) for systemic lupus erythematosus (SLE) showed markedly increased risk for atherosclerotic cardiovascular disease when blood levels of the drug were low and when long-term adherence was poor, a prospective study showed.

A Tribute to Daniel L. Kastner, MD, PhD (1951–2026)

Save

The rheumatology, genetics and NIH communities mourn for Dr. Daniel L. Kastner, who died on July 28, 2026, in Bethesda, Maryland, at age 74. The following are declarations, tributes, and memories dedicated to this mensch of a man, titan of science, memorable mentor and humble physician.

Arrhythmias in Autoimmune Rheumatic Disease

Save

A new review in the Journal of Cardiovascular Development and Disease (Tamirisa et al) synthesizes how systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis have an increased risk of arrhythmias and sudden cardiac death attributable to shared immune pathways.